Daily Pill Helps Maintain Weight Loss After Jabs

New Daily Pill Offers Hope for Long-Term Weight Management After Injection Therapy

A new daily pill could help people maintain their weight loss after stopping obesity injections. The drug, called orforglipron, has shown promising results in a landmark clinical trial. Researchers say it offers an effective and affordable alternative to injectable treatments. The findings have generated significant excitement across the global medical community.

The trial was presented at the European Congress on Obesity 2026 in Istanbul. Researchers published the study in the journal Nature Medicine. Eli Lilly, the manufacturer of the weight-loss jab Mounjaro, funded the research. The study marks a potential turning point in long-term obesity care.

One major challenge with GLP-1 injections is the risk of regaining weight after stopping. Previous studies found that patients typically regained two-thirds of lost weight within a year of stopping jabs. This new trial suggests that orforglipron could significantly reduce that rebound. Experts say the implications for public health are substantial.

What the Trial Found

The trial followed 376 patients in the United States who had already been on GLP-1 injections for 72 weeks. Those patients had been using either tirzepatide (sold as Mounjaro) or semaglutide (sold as Wegovy). They then switched to either a daily orforglipron tablet or a placebo for one year. Neither group knew which treatment they received.

Among patients who had previously used tirzepatide, those on orforglipron maintained 74.7% of their weight loss. The placebo group maintained only 49.2% of their earlier loss. For former semaglutide users, the pill group kept 79.3% of their weight off. The placebo group, by comparison, retained just 37.6%.

Beyond weight retention, the drug also sustained other health improvements. Participants on orforglipron maintained better blood pressure, cholesterol, and blood sugar levels. These are critical markers for cardiovascular and metabolic health. Researchers highlighted these additional benefits as particularly meaningful.

How the Drug Works

Orforglipron belongs to a class of drugs known as GLP-1 agonists. It works by lowering blood sugar levels and slowing food digestion. The drug also reduces appetite, helping patients feel full for longer. Crucially, patients take it as a once-daily tablet rather than an injection.

This oral format could make treatment far more accessible. Many patients find injections burdensome due to storage requirements, travel restrictions, and personal preference. The availability of an oral option could open treatment to a much wider group. Experts say this distinction matters greatly for long-term adherence.

Dr. Marie Spreckley, research programme manager at the University of Cambridge, praised the study’s real-world relevance. She said the trial reflected a “highly realistic clinical scenario.” She noted that many patients avoid injectable therapy due to cost, convenience, or personal preference. A viable oral transition option could therefore reshape long-term obesity care pathways.

Expert Reactions and Medical Context

Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine, called the findings significant. He argued that physicians should treat obesity more like other chronic diseases. “The beauty of treating obesity is you are treating all of these things,” he said. He added that effective obesity treatment eliminates the need to separately address cardiovascular risk factors.

About 30% of adults in the United Kingdom currently live with obesity. Those on Wegovy or Mounjaro take around seven medications for related health conditions on average. Treating obesity effectively could therefore reduce the overall medication burden. This has major implications for national health systems like the NHS.

However, researchers caution that more long-term data is still needed. Scientists do not yet know how durable the effects will be beyond the one-year trial period. Some experts suggest patients may need to remain on treatment indefinitely. Dr. Spreckley stressed that obesity is a chronic, relapsing condition that demands sustained management.

Cost and Availability

One of orforglipron’s most attractive features is its lower manufacturing cost. The drug costs approximately $149 per month in the United States at the lowest dose. By contrast, some GLP-1 injections cost over $1,000 per month in the US. Experts describe orforglipron as significantly cheaper to manufacture than current injectable alternatives.

The US Food and Drug Administration approved orforglipron last month. The drug could soon launch in the United Kingdom, though its UK pricing remains unknown. The drug has not yet received a UK market license. Authorities have not yet confirmed a timeline for a decision.

Rival manufacturer Novo Nordisk also developed an oral version of its GLP-1 drug Wegovy. The US has already approved that product. A UK decision on the Novo Nordisk oral drug remains pending. Competition between the two manufacturers could further drive down prices.

What This Means for Patients

Side effects from orforglipron were common in the trial but mostly mild. Patients reported nausea, constipation, and diarrhea as the most frequent complaints. These side effects mirror those seen with injectable GLP-1 treatments. Most participants tolerated them without discontinuing the drug.

The pill format removes several barriers that injectable drugs create. Patients no longer need to refrigerate medication or manage needles. Oral treatment also reduces anxiety for those uncomfortable with self-injection. These practical advantages could improve real-world treatment completion rates significantly.

Researchers stress that orforglipron is not a cure for obesity. The drug treats a chronic condition that requires ongoing, long-term management. Scientists urge health systems to invest in sustained treatment pathways. A cheaper oral pill represents one important step in that larger effort.